Mathias B. Bressel

305 Grattan St
Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

Journal: BMJ open

Published: September 03, 2026

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Journal: British journal of haematology

Published: July 15, 2026

ASO Visual Abstract: Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients With Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

ASO Visual Abstract: Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients With Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Journal: Annals of surgical oncology

Published: March 16, 2026

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

Journal: The Lancet. Oncology

Published: February 06, 2026

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: December 20, 2025

Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.

Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.

Journal: Oral oncology

Published: October 29, 2025

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Journal: Nature communications

Published: October 20, 2025

Applying Radiomics to Predict Outcomes in Patients with High-Grade Retroperitoneal Sarcoma Treated with Preoperative Radiotherapy.

Applying Radiomics to Predict Outcomes in Patients with High-Grade Retroperitoneal Sarcoma Treated with Preoperative Radiotherapy.

Journal: Journal of imaging

Published: October 08, 2025

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

Journal: The Lancet. Oncology

Published: October 07, 2025

Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data.

Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 30, 2025

Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Journal: Annals of surgical oncology

Published: September 02, 2025

Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.

Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery

Published: August 28, 2025

Showing 1-12 of 160

Last Updated: 09/26/2026